These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38788186)

  • 21. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
    Taylor LG; Canfield SE; Du XL
    Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review on the Effects of Androgen Deprivation Therapy (ADT) on Bone Health Status in Men with Prostate Cancer.
    Mohamad NV; Soelaiman IN; Chin KY
    Endocr Metab Immune Disord Drug Targets; 2017 Nov; 17(4):276-284. PubMed ID: 28925899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
    Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Androgen deprivation for advanced prostate cancer].
    Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
    Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Patil T; Bernard B
    Oncology (Williston Park); 2018 Sep; 32(9):470-4, CV3. PubMed ID: 30248169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan.
    Leith A; Ribbands A; Kim J; Clayton E; Gillespie-Akar L; Yang L; Ghate SR
    BMC Urol; 2022 Mar; 22(1):33. PubMed ID: 35277153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.
    Nead KT; Sinha S; Yang DD; Nguyen PL
    Urol Oncol; 2017 Nov; 35(11):664.e1-664.e9. PubMed ID: 28803700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
    Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
    Kunath F; Goebell PJ; Wullich B; Sikic D; Kahlmeyer A
    World J Urol; 2020 Mar; 38(3):601-611. PubMed ID: 30830274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
    Shahani S; Braga-Basaria M; Basaria S
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis.
    Yunfeng G; Weiyang H; Xueyang H; Yilong H; Xin G
    Medicine (Baltimore); 2017 Jul; 96(27):e7368. PubMed ID: 28682886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Androgen deprivation for prostate cancer: when and how, the good and the bad.
    Chi KN; Nguyen PL; Higano CS
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714494
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study.
    Wu LM; Diefenbach MA; Gordon WA; Cantor JB; Cherrier MM
    Urol Oncol; 2013 Nov; 31(8):1533-8. PubMed ID: 22975107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.
    Sevilla C; Maliski SL; Kwan L; Connor SE; Litwin MS
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):237-43. PubMed ID: 22289781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.